Skip to main content

The Tri-Institutional Therapeutics Discovery Institute renews partnerships with Takeda and Bridge Medicines

The Rockefeller University, along with Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, today announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.

A pioneering academic-industry collaboration, the Tri-I TDI was established in 2013 to expedite early-stage drug discovery of novel therapies, including small molecules and biologics. To date, work done within the Tri-I TDI has resulted in the launch of two New York City–based companies and the licensing of six therapeutic discovery programs, with additional programs under active negotiation.

As the Tri-I TDI’s industry partner, Takeda contributes financial support, along with a wealth of drug discovery knowledge and expertise and best practices gained from its position as an established industry leader in the pharmaceutical sector.

In 2016, the Tri-I TDI announced the launch of Bridge Medicines in partnership with Takeda and healthcare investment firms Deerfield Management Company and Bay City Capital. Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded, and professionally staffed path from concept to drug candidate to efficiently develop innovative therapeutics for the treatment of human diseases.

Read the full press release here.